Comparing QLS32015 to standard treatments for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with multiple myeloma that can be measured with blood or urine tests.
- You have had at least 3 prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
- You do not have active plasma cell leukemia or light chain amyloidosis.
- Your disease is not resistant to pomalidomide or selinexor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
This trial tests an experimental drug called QLS4131 for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if the drug can help control the cancer.
This study tests a new drug called IBI3003 in people whose multiple myeloma (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can shrink the cancer and help patients live longer.
This trial tests a new drug called QI-019B for people with multiple myeloma whose cancer has come back or stopped responding to other treatments. The goal is to see if it is safe and can help shrink or slow the cancer.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.